Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

α-Synuclein in synaptic function and dysfunction
Manu Sharma, Jacqueline Burré
Trends in Neurosciences (2022) Vol. 46, Iss. 2, pp. 153-166
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Alpha Synuclein: Neurodegeneration and Inflammation
Gianluigi Forloni
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5914-5914
Open Access | Times Cited: 54
Targeting synapse function and loss for treatment of neurodegenerative diseases
Borislav Dejanovic, Morgan Sheng, Jesse E. Hanson
Nature Reviews Drug Discovery (2023) Vol. 23, Iss. 1, pp. 23-42
Closed Access | Times Cited: 40
Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives
Virendra Kumar Yadav, Seshathiri Dhanasekaran, Nisha Choudhary, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access | Times Cited: 2
Automated procedure to detect subtle motor alterations in the balance beam test in a mouse model of early Parkinson’s disease
Raphaëlle Bidgood, Maider Zubelzu, José Ángel Ruíz-Ortega, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Interplay of α-synuclein with Lipid Membranes: Cooperative Adsorption, Membrane Remodeling and Coaggregation
Katarzyna Makasewicz, Sara Linse, Emma Sparr
JACS Au (2024) Vol. 4, Iss. 4, pp. 1250-1262
Open Access | Times Cited: 9
Research Priorities on the Role of α‐Synuclein in Parkinson's Disease Pathogenesis
Jacqueline Burré, Robert H. Edwards, Glenda M. Halliday, et al.
Movement Disorders (2024) Vol. 39, Iss. 10, pp. 1663-1678
Open Access | Times Cited: 8
A Wonderful Journey: The Diverse Roles of Adenosine Deaminase Action on RNA 1 (ADAR1) in Central Nervous System Diseases
Lin Cheng, Ziying Liu, Chunxiao Shen, et al.
CNS Neuroscience & Therapeutics (2025) Vol. 31, Iss. 1
Open Access | Times Cited: 1
Identification of novel phenolic inhibitors from traditional Chinese medicine against toxic α-synuclein aggregation via regulating phase separation
Linwei Yu, Xi Li, Tianyi Shi, et al.
International Journal of Biological Macromolecules (2025) Vol. 297, pp. 139875-139875
Closed Access | Times Cited: 1
Pathogenesis of Parkinson’s Disease
Bin Xiao, Zhidong Zhou, Yinxia Chao, et al.
Neurologic Clinics (2025)
Closed Access | Times Cited: 1
The Possible Role of Brain-derived Neurotrophic Factor in Epilepsy
Raed AlRuwaili, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Neurochemical Research (2023) Vol. 49, Iss. 3, pp. 533-547
Open Access | Times Cited: 17
Gut–Brain Axis in Focus: Polyphenols, Microbiota, and Their Influence on α-Synuclein in Parkinson’s Disease
Elizabeth Riegelman, Kathy S. Xue, Jia-Sheng Wang, et al.
Nutrients (2024) Vol. 16, Iss. 13, pp. 2041-2041
Open Access | Times Cited: 7
Ultrasound-Assisted CRISPRi-Exosome for Epigenetic Modification of α-Synuclein Gene in a Mouse Model of Parkinson’s Disease
Weirong Kong, Xin Li, Xiaoyu Guo, et al.
ACS Nano (2024) Vol. 18, Iss. 11, pp. 7837-7851
Closed Access | Times Cited: 6
Neural stem cells for Parkinson’s disease management: Challenges, nanobased support, and prospects
Tuba Öz, Ajeet Kaushik, Małgorzata Kujawska
World Journal of Stem Cells (2023) Vol. 15, Iss. 7, pp. 687-700
Open Access | Times Cited: 15
Alterations in neurotransmitter co-release in Parkinson's disease
Kelsey Barcomb, Christopher Ford
Experimental Neurology (2023) Vol. 370, pp. 114562-114562
Open Access | Times Cited: 15
Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson’s disease
Fabrizio Angius, Ignazia Mocci, Tommaso Ercoli, et al.
Journal of Neurology (2023) Vol. 270, Iss. 11, pp. 5613-5621
Open Access | Times Cited: 14
Identifying potential genes driving ferroptosis in the substantia nigra and dopaminergic neurons in Parkinson's disease
Arunaloke Chakrabarti, Sonia Verma
Molecular and Cellular Neuroscience (2025) Vol. 132, pp. 103993-103993
Closed Access
Order-to-Disorder and Disorder-to-Order Transitions of Proteins upon Binding to Phospholipid Membranes: Common Ground and Dissimilarities
Reinhard Schweitzer‐Stenner
Biomolecules (2025) Vol. 15, Iss. 2, pp. 198-198
Open Access
Transcriptional dysregulation in the cerebellum triggered by oligodendroglial α-synucleinopathy: insights from a transgenic mouse into the early disease mechanisms of MSA
Antonio Heras-Garvín, Lisa Fellner, Roberta Granata, et al.
Journal of Neural Transmission (2025)
Open Access
GRP94 mediates blood-brain barrier permeation and substantia nigra-specific drug distribution in Parkinson’s disease
Ziyan Lv, Yuteng Zeng, Tangfeng Lv, et al.
Colloids and Surfaces B Biointerfaces (2025), pp. 114585-114585
Closed Access
Prasinezumab slows motor progression in Parkinsons disease: beyond the clinical data
Bin Xiao, Eng‐King Tan
npj Parkinson s Disease (2025) Vol. 11, Iss. 1
Open Access
Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer’s pathophysiological biomarkers
Alba Cervantes‐González, Julie Goossens, E. Vera Campuzano, et al.
Alzheimer s Research & Therapy (2025) Vol. 17, Iss. 1
Open Access
Balancing act: lipid-to-protein ratios steer the aggregation fate of α-synuclein
Christian Blum, Mireille M. A. E. Claessens
Trends in Biochemical Sciences (2025)
Closed Access
A personalised and comprehensive approach is required to suppress or replenish SNCA for Parkinson’s disease
Dunhui Li, Wai Yan Yau, Shengdi Chen, et al.
npj Parkinson s Disease (2025) Vol. 11, Iss. 1
Open Access
Regulation of polyamine interconversion enzymes affects α-Synuclein levels and toxicity in a Drosophila model of Parkinson's disease
Bedri Ranxhi, Zoya R. Bangash, Zachary M. Chbihi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Preclinical assessment of a ganglioside-targeted therapy for Parkinson’s disease with the first-in-class adaptive peptide AmyP53
Jacques Fantini, Fodil Azzaz, Anaïs Aulas, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top